Panbela Therapeutics Future Growth
Future criteria checks 0/6
Panbela Therapeutics's earnings are forecast to decline at 4.3% per annum while its annual revenue is expected to grow at 82.4% per year. EPS is expected to grow by 53% per annum.
Key information
-4.3%
Earnings growth rate
53.0%
EPS growth rate
Biotechs earnings growth | 31.4% |
Revenue growth rate | 82.4% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 11 Apr 2023 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | N/A | -52 | N/A | N/A | 2 |
12/31/2024 | N/A | -32 | N/A | N/A | 2 |
12/31/2023 | N/A | -22 | N/A | N/A | 2 |
12/31/2022 | N/A | -35 | -16 | -15 | N/A |
9/30/2022 | N/A | -34 | -13 | -12 | N/A |
6/30/2022 | N/A | -31 | -12 | -12 | N/A |
3/31/2022 | N/A | -12 | -9 | -9 | N/A |
12/31/2021 | N/A | -10 | -7 | -7 | N/A |
9/30/2021 | N/A | -7 | -6 | -6 | N/A |
6/30/2021 | N/A | -7 | -6 | -6 | N/A |
3/31/2021 | N/A | -5 | -5 | -5 | N/A |
12/31/2020 | N/A | -5 | -4 | -4 | N/A |
9/30/2020 | N/A | -5 | -4 | -4 | N/A |
6/30/2020 | N/A | -5 | -3 | -3 | N/A |
3/31/2020 | N/A | -6 | -3 | -3 | N/A |
12/31/2019 | N/A | -6 | -3 | -3 | N/A |
9/30/2019 | N/A | -6 | -2 | -2 | N/A |
6/30/2019 | N/A | -6 | -2 | -2 | N/A |
3/31/2019 | N/A | -6 | -3 | -3 | N/A |
12/31/2018 | N/A | -6 | -2 | -2 | N/A |
9/30/2018 | N/A | -7 | -3 | -3 | N/A |
6/30/2018 | N/A | -8 | -3 | -3 | N/A |
3/31/2018 | N/A | -7 | -3 | -3 | N/A |
12/31/2017 | N/A | -10 | -3 | -3 | N/A |
9/30/2017 | N/A | -10 | -3 | -3 | N/A |
6/30/2017 | N/A | -10 | -4 | -4 | N/A |
3/31/2017 | N/A | -10 | -3 | -3 | N/A |
12/31/2016 | N/A | -5 | -2 | -2 | N/A |
9/30/2016 | N/A | -4 | N/A | -2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: X70 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: X70 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: X70 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: X70 is forecast to have no revenue next year.
High Growth Revenue: X70 is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if X70's Return on Equity is forecast to be high in 3 years time